ArticleImmunology2009
Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.
Article in Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- The unique immune evasion mechanisms of the mpox virus and their implication for developing new vaccines and immunotherapies.Virologica Sinica · 2024Review
- Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy.Clinical and experimental medicine · 2024Review
- Orthopoxvirus Zoonoses-Do We Still Remember and Are Ready to Fight?Pathogens (Basel, Switzerland) · 2023Review
- Modulation of Macrophage Polarization by Viruses: Turning Off/On Host Antiviral Responses.Frontiers in microbiology · 2022Review
- Article
- Article
- Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.Pathogens (Basel, Switzerland) · 2021Article
- Identification of protective T-cell antigens for smallpox vaccines.Cytotherapy · 2020Article
- Selective reconstitution of IFN‑γ gene function in Ncr1+ NK cells is sufficient to control systemic vaccinia virus infection.PLoS pathogens · 2020Article
- Article
- Functional paralysis of GM-CSF-derived bone marrow cells productively infected with ectromelia virus.PloS one · 2017Article
- Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells.PLoS neglected tropical diseases · 2016Article
- Highly immunogenic variant of attenuated vaccinia virus.Doklady. Biochemistry and biophysics · 2016Article
- Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.Journal of virology · 2015Article
- Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.Immunology · 2014Article
- Orthopoxvirus genes that mediate disease virulence and host tropism.Advances in virology · 2012Article
- Antigen presentation assays to investigate uncharacterized immunoregulatory genes.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Immune modulation in primary vaccinia virus zoonotic human infections.Clinical & developmental immunology · 2012Article
- Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.Journal of virology · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Vaccinia virus (VACV) is the current live virus vaccine used to protect humans against smallpox and monkeypox, but its use is contraindicated in several populations because of its virulence. It is therefore important to elucidate the immune evasion mechanisms of VACV. We found that VACV infection of antigen-presenting cells (APCs) significantly decreased major histocompatibility complex (MHC) II antigen presentation and decreased synthesis of 13 chemokines and cytokines, suggesting a potent viral mechanism for immune evasion. In these model systems, responding T cells were not directly affected by virus, indicating that VACV directly affects the APC. VACV significantly decreased nitric oxide production by peritoneal exudate cells and the RAW macrophage cell line in response to lipopolysaccharide (LPS) and interferon (IFN)-gamma, decreased class II MHC expression on APCs, and induced apoptosis in macrophages and dendritic cells. However, VACV decreased antigen presentation by 1153 B cells without apparent apoptosis induction, indicating that VACV differentially affects B lymphocytes and other APCs. We show that the key mechanism of VACV inhibition of antigen presentation may be its reduction of antigenic peptide loaded into the cleft of MHC class II molecules. These data indicate that VACV evades the host immune response by impairing critical functions of the APC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.